文章摘要 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical Trials
Definition, classification and diagnosis of pulmonary hypertension
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
Viridans Streptococcal Biofilm Evades Immune Detection and Contributes to Inflammation and Rupture of Atherosclerotic Plaques
Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium
Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person
TRAP1 drives smooth muscle cell senescence and promotes atherosclerosis via HDAC3-primed histone H4 lysine 12 lactylation

|<<... 170 171 172 173 174 175 176 177 >>|

Original Research

May 11，2024

JOURNAL：Lancet

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial

葛震、阚静、高晓飞、陈绍良、Gregg W. Stone

6981

Full Text PDF